Sofinnova Partners has announced a new collaboration with NVIDIA to accelerate the AI capabilities of its life sciences portfolio companies, offering a powerful edge in a market estimated to exceed $100 billion.

The agreement sees selected Sofinnova-backed startups gain access to NVIDIA’s high-performing DGX Cloud Lepton platform, which provides scalable GPU infrastructure typically used by the world’s biggest technology companies. The goal is to cut data-processing times from months to days, positioning Europe at the forefront of the AI-driven drug discovery race.

Among the first startups to benefit are BioCorteX, Bioptimus, Cure51 and Latent Labs. These companies focus on digital medicine and are developing tools and therapies based on complex computational models. With the support of NVIDIA DGX Cloud Lepton, they can now process vast biological data sets at unprecedented speed and efficiency.

Cure51, which investigates the biology of long-term cancer survivors, recently tested NVIDIA Parabricks, a genomics analysis toolkit accelerated by GPU technology. Using NVIDIA H100 GPUs, the company achieved up to 17 times faster processing, while switching to NVIDIA L4 GPUs provided more than double the cost savings compared to CPUs. This advancement enables faster analysis of genomic data and a faster route to meaningful clinical insights.

“This collaboration supercharges computation for life sciences innovation,” said Antoine Papiernik, chairman and managing partner at Sofinnova Partners.

“The convergence of biology, AI, computation, and data isn’t just our investment thesis—it’s the defining battleground of the next decade. From our Digital Medicine strategy to our own proprietary AI platform Sofinnova.ai, we recognize the transformative potential of AI across our entire domain. By securing access to NVIDIA’s infrastructure, we’re not just funding companies; we’re empowering them with the computational backbone needed to outperform incumbents and redefine what’s possible in drug discovery, precision medicine, and scalable solutions that address both human health and sustainability.”

DGX Cloud Lepton, developed by NVIDIA, connects developers to a global network of advanced GPUs, including the company’s latest Blackwell architecture, designed specifically for generative AI and large-scale biological data analysis.

The collaboration is part of Sofinnova’s broader Digital Medicine strategy, which supports startups combining AI with biological and clinical data to uncover new diagnostics and therapies.

With high-speed computing now a critical element of drug discovery and precision health, this partnership aims to help European startups bridge the gap between scientific research and scalable, commercial solutions.